Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229449 | 0.89 | TGFBR1 (0.56) | TGFBR1PRKD1LRRK2KDRRIPK1 | |
| SCHEMBL2197137 | 0.86 | TGFBR1 (0.50) | MAPTTGFBR1PRKD1LRRK2KDR | |
| SCHEMBL28411768 | 0.86 | RIPK1 (0.48) | TGFBR1LRRK2KDRRIPK1SYK | |
| SCHEMBL2201532 | 0.82 | KDR (0.47) | TGFBR1PRKD1LRRK2KDRRIPK1 | |
| SCHEMBL2198086 | 0.80 | TGFBR1 (0.52) | MAPTTGFBR1PRKD1LRRK2KDR | |
| SCHEMBL2202465 | 0.80 | EGFR (0.61) | TGFBR1PRKD1KDREGFR | |
| SCHEMBL2197036 | 0.79 | ABCG2 (0.54) | MAPTTGFBR1PRKD1LRRK2KDR | |
| SCHEMBL2202398 | 0.77 | IKBKB (0.47) | MAPTTGFBR1PRKD1LRRK2KDR | |
| SCHEMBL2202747 | 0.76 | TGFBR1 (0.45) | TGFBR1PRKD1LRRK2KDRRIPK1 | |
| SCHEMBL6494070 | 0.75 | FLT1 (0.44) | TGFBR1PRKD1LRRK2KDRRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | claimed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | MAPT 4617/4885TGFBR1 1039/4885PRKD1 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.